For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Legend Biotech Corp ADR (NASDAQ: LEGN) closed at $45.14 down -0.35% from its previous closing price of $45.30. In other words, the price has decreased by -$0.35 from its previous closing price. On the day, 0.96 million shares were traded. LEGN stock price reached its highest trading level at $46.46 during the session, while it also had its lowest trading level at $45.055.
Ratios:
For a deeper understanding of Legend Biotech Corp ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.83 and its Current Ratio is at 6.92. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
On April 03, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $82.
On March 13, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $86.Raymond James initiated its Outperform rating on March 13, 2024, with a $86 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 8240577536 and an Enterprise Value of 15442883584. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.80 while its Price-to-Book (P/B) ratio in mrq is 6.56. Its current Enterprise Value per Revenue stands at 54.158 whereas that against EBITDA is -35.788.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.09, which has changed by -0.31230956 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $77.32, while it has fallen to a 52-week low of $44.06. The 50-Day Moving Average of the stock is -22.27%, while the 200-Day Moving Average is calculated to be -28.28%.
Shares Statistics:
For the past three months, LEGN has traded an average of 976.96K shares per day and 1352690 over the past ten days. A total of 181.91M shares are outstanding, with a floating share count of 180.50M. Insiders hold about 0.78% of the company’s shares, while institutions hold 46.91% stake in the company. Shares short for LEGN as of 1713139200 were 10983290 with a Short Ratio of 11.24, compared to 1710460800 on 10509813. Therefore, it implies a Short% of Shares Outstanding of 10983290 and a Short% of Float of 11.62.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.75, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.09 and low estimates of -$0.77.
Analysts are recommending an EPS of between -$0.5 and -$2.73 for the fiscal current year, implying an average EPS of -$1.47. EPS for the following year is -$0.62, with 10.0 analysts recommending between $0.42 and -$1.71.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $153.36M this quarter.It ranges from a high estimate of $202.5M to a low estimate of $80M. As of the current estimate, Legend Biotech Corp ADR’s year-ago sales were $36.34MFor the next quarter, 11 analysts are estimating revenue of $127.55M. There is a high estimate of $168.2M for the next quarter, whereas the lowest estimate is $85M.
A total of 17 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $676.87M, while the lowest revenue estimate was $450M, resulting in an average revenue estimate of $580.83M. In the same quarter a year ago, actual revenue was $285.14MBased on 16 analysts’ estimates, the company’s revenue will be $1.08B in the next fiscal year. The high estimate is $1.53B and the low estimate is $841.7M.
